MARC details
| 000 -LEADER |
|---|
| fixed length control field |
05346nam a22005535i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20231109085816.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
220801s2022 sz | s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9783030972202 |
| 024 7# - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1007/978-3-030-97220-2 |
| Source of number or code |
doi |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
TR-AnTOB |
| Language of cataloging |
eng |
| Description conventions |
rda |
| Transcribing agency |
TR-AnTOB |
| 060 ## - NATIONAL LIBRARY OF MEDICINE CALL NUMBER |
|---|
| Classification number |
WN 250 |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MMN |
| Source |
bicssc |
|
|---|
| Subject category code |
MED080000 |
| Source |
bisacsh |
|
|---|
| Subject category code |
MKR |
| Source |
thema |
| 096 ## - LOCALLY ASSIGNED NLM-TYPE CALL NUMBER (OCLC) |
|---|
| Classification number |
WN250EBK |
| 041 ## - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
İngilizce |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Radionuclide Therapy |
| Medium |
[electronic resource] / |
| Statement of responsibility, etc. |
edited by Recep Bekiş, Berna Polack, Murat Fani Bozkurt. |
| 250 ## - EDITION STATEMENT |
|---|
| Edition statement |
1st ed. 2022. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
Cham : |
| Name of producer, publisher, distributor, manufacturer |
Springer International Publishing : |
| -- |
Imprint: Springer, |
| Date of production, publication, distribution, manufacture, or copyright notice |
2022. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
1 online resource |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Content type code |
txt |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
computer |
| Media type code |
c |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
online resource |
| Carrier type code |
cr |
| Source |
rdacarrier |
| 347 ## - DIGITAL FILE CHARACTERISTICS |
|---|
| File type |
text file |
| Encoding format |
PDF |
| Source |
rda |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Part-1: Basic Information. Basic properties and preparation of radiopharmaceuticals used in radionuclide therapy -- Physical Bases of Radionuclide Therapy (Biological Effects and Properties of Particle Radiation) -- Fundamentals of radiation safety and dosimetric approach in radionuclide therapy applications. Part-2: Clinical Information: Thyroid Diseases. Radionuclide Therapy in Benign Thyroid Diseases: Nodular Goiter Disease -- Radionuclide Therapy in Benign Thyroid Diseases: Graves' Disease -- Radionuclide Therapy in Malignant Thyroid Diseases: Differentiated Thyroid Cancer -- Radionuclide Therapy in Malignant Thyroid Diseases: Medullary Thyroid Cancer -- Systemic Treatments and related side effects in Thyroid Cancer. Part-2: Clinical Information: Neuroendocrine Tumors. Radionuclide Therapy in Neuroendocrine Tumors. Systemic Treatments and related side effects in Neuroendocrine Tumors. Part-4: Clinical Information: Neuroectodermal Tumors. Radionuclide Therapy in Neuroectodermal Tumors -- Systemic Treatments and related side effects in Neuroectodermal Tumors. Part-5: Clinical Information: Liver Tumors. Radionuclide Therapy in Liver Tumors. Systemic Treatments and related side effects in Liver Tumors. Part-6: Clinical Information: Prostate Cancer. Radionuclide Therapy in Prostate Cancer -- Systemic Treatments and related side effects in Prostate Cancer. Part-7: Clinical Information: Bone and Joint Diseases. Radionuclide Therapy in Joint Diseases: Radiosynovectomy -- Radionuclide Pain Palliation Therapy -- Radionuclide Therapy with Alpha Emitting Agents in Bone Metastases. Part-8: Clinical Information: Lymphoproliferative Diseases. Radionuclide Therapy in Lymphoproliferative Diseases. Part-9: Radioimmunotherapy. Basics and clinical applications of radioimmunotherapy. Part-10: Intracavitary Radionuclide Therapy. Intracavitary radionuclide applications. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
The main purpose of this book is to create a reference for the indications, contraindications, patient selection, treatment practice, treatment side effect management, and follow-up of radionuclide treatments. Besides standard methods such as surgery, chemotherapy, radiotherapy, and hormone therapy, newly developed biological treatments, targeted treatments, personalized treatments, external beam radiotherapy, and targeted radionuclide treatments have begun to take their place in professional practice. Nuclear medicine, in addition to its role as a tracer of cancer, also assumes the role of treating with radioactive molecules directed to the cancer it traces. These traceable next-generation radionuclide treatments, whose efficacy and reliability have been proven and where diagnosis, treatment, and follow-up are carried out together, are increasingly included in oncology practice together with the new developed radiopharmaceuticals, ensuring a high rate of damage to cancer cells while protecting the surrounding normal tissues. Molecular cancer treatment will become more effective with individualized next-generation traceable radionuclide treatments, which will be shaped by genetic studies in the future. Radionuclide treatments for many cancer types and benign diseases are presented by experienced nuclear medicine experts in the light of their own experience and case studies, while systemic treatments in common cancer types and side effect management of these treatments are summarized by medical oncologists. This book will be of interest to nuclear medicine physicians as well as oncologists. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Nuclear medicine. |
|
|---|
| Topical term or geographic name entry element |
Oncology. |
|
|---|
| Topical term or geographic name entry element |
Endocrinology. |
|
|---|
| Topical term or geographic name entry element |
Gastroenterology. |
|
|---|
| Topical term or geographic name entry element |
Nuclear Medicine. |
|
|---|
| Topical term or geographic name entry element |
Oncology. |
|
|---|
| Topical term or geographic name entry element |
Endocrinology. |
|
|---|
| Topical term or geographic name entry element |
Gastroenterology. |
| 653 #0 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Radiotherapy |
|
|---|
| Uncontrolled term |
Nuclear Medicine |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Bekiş, Recep. |
| Relator term |
editor. |
| Relator code |
edt |
| -- |
http://id.loc.gov/vocabulary/relators/edt |
|
|---|
| Personal name |
Polack, Berna. |
| Relator term |
editor. |
| Relator code |
edt |
| -- |
http://id.loc.gov/vocabulary/relators/edt |
|
|---|
| Personal name |
Bozkurt, Murat Fani. |
| Relator term |
editor. |
| Relator code |
edt |
| -- |
http://id.loc.gov/vocabulary/relators/edt |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="https://doi.org/10.1007/978-3-030-97220-2">https://doi.org/10.1007/978-3-030-97220-2</a> |
| Materials specified |
Springer eBooks |
| Public note |
Online access link to the resource |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
National Library of Medicine |
| Koha item type |
E-Book |
